Celon Pharma (FRA:8RP) YoY EBITDA Growth : 1,212.50% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Celon Pharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Celon Pharma's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 1,212.50%.

Celon Pharma's EBITDA per Share for the three months ended in Sep. 2024 was €0.32.

Celon Pharma YoY EBITDA Growth Historical Data

The historical data trend for Celon Pharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celon Pharma YoY EBITDA Growth Chart

Celon Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-48.81

3.31

-8.97

-69.72

253.49

Celon Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															500.00	12.50	-60.00	-90.32	1,212.50

Celon Pharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Celon Pharma's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(0.152	-	0.043)	/	\| 0.043 \|
=	253.49 %

Celon Pharma's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2024 )
=	(EBITDA per Share (Q: Sep. 2024 )	-	EBITDA per Share (Q: Sep. 2023 ))	/	\| EBITDA per Share (Q: Sep. 2023 )) \|
=	(0.315	-	0.024)	/	\| 0.024 \|
=	1,212.50 %

Celon Pharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Celon Pharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Celon Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celon Pharma SA (FRA:8RP) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CLN:Poland

Address

Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092

Website

http://www.celonpharma.com

Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.

Celon Pharma Headlines

No Headlines